Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Account Payables (2017 - 2025)

Protagonist Therapeutics' Change in Account Payables history spans 9 years, with the latest figure at -$307000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 136.33% year-over-year to -$307000.0; the TTM value through Dec 2025 reached $3.7 million, up 342.16%, while the annual FY2025 figure was $3.7 million, 342.16% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$307000.0 at Protagonist Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.6 million in Q2 2021 and bottomed at -$10.3 million in Q3 2021.
  • The 5-year median for Change in Account Payables is $37000.0 (2022), against an average of -$50842.1.
  • The largest YoY upside for Change in Account Payables was 644.4% in 2021 against a maximum downside of 24960.98% in 2021.
  • A 5-year view of Change in Account Payables shows it stood at -$222000.0 in 2021, then surged by 116.67% to $37000.0 in 2022, then tumbled by 1713.51% to -$597000.0 in 2023, then soared by 241.54% to $845000.0 in 2024, then plummeted by 136.33% to -$307000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Change in Account Payables are -$307000.0 (Q4 2025), $2.4 million (Q3 2025), and $375000.0 (Q2 2025).